JP2018528985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528985A5 JP2018528985A5 JP2018533979A JP2018533979A JP2018528985A5 JP 2018528985 A5 JP2018528985 A5 JP 2018528985A5 JP 2018533979 A JP2018533979 A JP 2018533979A JP 2018533979 A JP2018533979 A JP 2018533979A JP 2018528985 A5 JP2018528985 A5 JP 2018528985A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- epilepsy
- oral liquid
- purity
- cannabidiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 3
- 229950011318 cannabidiol Drugs 0.000 claims 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 3
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- 239000002285 corn oil Substances 0.000 claims 2
- 235000005687 corn oil Nutrition 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102015024165A BR102015024165A2 (pt) | 2015-09-18 | 2015-09-18 | composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
| BRBR102015024165-8 | 2015-09-18 | ||
| PCT/BR2016/050231 WO2017045053A1 (pt) | 2015-09-18 | 2016-09-16 | Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528985A JP2018528985A (ja) | 2018-10-04 |
| JP2018528985A5 true JP2018528985A5 (OSRAM) | 2021-02-04 |
Family
ID=58288018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533979A Pending JP2018528985A (ja) | 2015-09-18 | 2016-09-16 | カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180264121A1 (OSRAM) |
| EP (1) | EP3351242A4 (OSRAM) |
| JP (1) | JP2018528985A (OSRAM) |
| CN (1) | CN108366988A (OSRAM) |
| AU (1) | AU2016322148A1 (OSRAM) |
| BR (2) | BR102015024165A2 (OSRAM) |
| CA (1) | CA2998739A1 (OSRAM) |
| WO (1) | WO2017045053A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3658137A1 (en) * | 2017-07-27 | 2020-06-03 | Shaaban, Basil Adil | Cannabinoid composition having an optimized fatty acid excipient profile |
| WO2019079208A1 (en) * | 2017-10-16 | 2019-04-25 | Joshua Raderman | CANNABINOID FORMULATIONS AND METHODS COMPRISING THE C60 ANTIOXIDANT |
| WO2019153073A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
| EP3787614B1 (en) | 2018-05-03 | 2024-07-31 | SCF Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject |
| US20220304963A1 (en) * | 2018-07-27 | 2022-09-29 | Basil Shaaban | Composition having an optimized fatty acid excipient profile |
| IL261132A (en) * | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| WO2020044118A1 (en) * | 2018-08-27 | 2020-03-05 | Emerald Health Therapeutics Canada Inc. | Improved cannabinoid bioavailability |
| CN108968071A (zh) * | 2018-09-26 | 2018-12-11 | 江西中医药大学 | 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用 |
| EP3893673A4 (en) | 2018-12-14 | 2023-05-03 | Natural Extraction Systems, LLC | COMPOSITIONS AND METHODS RELATED TO ANIONIC CANNABINOID MOLECULES |
| US11026888B1 (en) | 2019-01-04 | 2021-06-08 | Nutrition Therapeutics, Inc. | Functional beverage compositions and methods of using and making same |
| CA3040547C (en) * | 2019-04-17 | 2021-12-07 | Medcan Pharma A/S | Cannabinoid lozenge formulation |
| AU2020318671B2 (en) * | 2019-07-21 | 2021-12-23 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US20220288014A1 (en) * | 2019-08-08 | 2022-09-15 | Neptune Wellness Solutions Inc. | Oral formulations of cannabis extracts and methods of making same |
| WO2021041637A1 (en) * | 2019-08-28 | 2021-03-04 | Natural Extraction Systems, LLC | Compositions comprising cannabinoid ions dissolving in glycerol |
| BR112022002409A2 (pt) * | 2019-09-09 | 2022-04-26 | Cardiol Therapeutics Inc | Composições medicinais estáveis de canabidiol |
| CN113694049B (zh) * | 2020-05-21 | 2022-11-22 | 汉义生物科技（北京）有限公司 | 大麻素类化合物及其在治疗帕金森症中的应用 |
| CN111603443B (zh) * | 2020-06-12 | 2022-06-28 | 苏州旺山旺水生物医药有限公司 | 一种稳定的cbd组合物及其应用 |
| WO2022026960A1 (en) | 2020-07-31 | 2022-02-03 | Natural Extraction Systems, LLC | Compositions and methods related to excipients and cannabinoid formulations |
| US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| JP2023039414A (ja) * | 2021-09-08 | 2023-03-20 | 株式会社東洋新薬 | 経口組成物 |
| EP4601629A1 (en) * | 2022-10-12 | 2025-08-20 | Leiutis Pharmaceuticals LLP | Novel liquid oral formulations of cannabidiol |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
| CA3236758A1 (en) * | 2023-07-24 | 2025-06-17 | Poviva Corp | Compositions and methods for treating epilepsy |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0548238A1 (en) * | 1990-09-13 | 1993-06-30 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| US6703418B2 (en) * | 1991-02-26 | 2004-03-09 | Unimed Pharmaceuticals, Inc. | Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection |
| GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| KR101166394B1 (ko) * | 2004-02-06 | 2012-07-23 | 추가이 세이야쿠 가부시키가이샤 | Ｅｄ-71 제제 |
| US20070104741A1 (en) * | 2005-11-07 | 2007-05-10 | Murty Pharmaceuticals, Inc. | Delivery of tetrahydrocannabinol |
| US20140357708A1 (en) * | 2005-11-07 | 2014-12-04 | Murty Pharmaceuticals, Inc. | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| US8980940B2 (en) * | 2006-11-10 | 2015-03-17 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| CA2698752A1 (en) * | 2007-08-06 | 2009-02-12 | Insys Therapeutics Inc. | Oral cannabinoid liquid formulations and methods of treatment |
| US8222292B2 (en) * | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| EP2642982A2 (en) * | 2010-11-22 | 2013-10-02 | Johnson Matthey Public Limited Company | Stable cannabinoid compositions and methods for making and storing them |
| CN104363890B (zh) * | 2012-05-07 | 2018-01-26 | 回音制药公司 | 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元 |
| US9763991B2 (en) * | 2013-06-13 | 2017-09-19 | Cannabis Science International Holding B.V. | Composition for the treatment of neurobehavioral disorders |
| CA2950424C (en) * | 2014-05-29 | 2023-03-14 | Insys Pharma, Inc. | Stable cannabinoid formulations |
| GB2542155B (en) * | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
-
2015
- 2015-09-18 BR BR102015024165A patent/BR102015024165A2/pt not_active Application Discontinuation
-
2016
- 2016-09-16 BR BR112018005423-2A patent/BR112018005423B1/pt active IP Right Grant
- 2016-09-16 JP JP2018533979A patent/JP2018528985A/ja active Pending
- 2016-09-16 CA CA2998739A patent/CA2998739A1/en not_active Abandoned
- 2016-09-16 EP EP16845409.8A patent/EP3351242A4/en active Pending
- 2016-09-16 CN CN201680057462.4A patent/CN108366988A/zh active Pending
- 2016-09-16 US US15/760,918 patent/US20180264121A1/en not_active Abandoned
- 2016-09-16 WO PCT/BR2016/050231 patent/WO2017045053A1/pt not_active Ceased
- 2016-09-16 AU AU2016322148A patent/AU2016322148A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528985A5 (OSRAM) | ||
| CN103635189B (zh) | 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗 | |
| SG10201903474PA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| JP2016528301A5 (OSRAM) | ||
| JP2014517050A5 (OSRAM) | ||
| JP2018513107A5 (OSRAM) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2016535777A5 (OSRAM) | ||
| JP2016513717A5 (OSRAM) | ||
| JP2018021046A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2015501783A5 (OSRAM) | ||
| JP2015536307A5 (OSRAM) | ||
| JP2015520151A5 (OSRAM) | ||
| JP2016027060A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| JP2015524423A5 (OSRAM) | ||
| JP2017519807A5 (OSRAM) | ||
| JP2017526747A5 (OSRAM) | ||
| JP2016523907A5 (OSRAM) | ||
| JP2015500223A5 (OSRAM) | ||
| JP2016505039A5 (OSRAM) | ||
| JP2017507980A5 (OSRAM) |